Products & Services · % Change
Abiomed — % Change
Johnson & Johnson Abiomed — % Change remained flat by 0.0% to 4.3% in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 17.9%, from 3.6% to 4.3%. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityVolatile
First reportedQ1 2024
Last reportedQ4 2025Feb 11, 2026
How to read this metric
A positive percentage indicates accelerating growth and successful integration, whereas a negative percentage suggests slowing demand or operational challenges within the segment.
Detailed definition
This metric measures the period-over-period percentage growth or decline in revenue for the Abiomed product line. It iso...
Peer comparison
Comparable to organic or segment-specific revenue growth rates reported by medical technology companies for their high-growth product lines.
Metric ID:
jnj_segment_abiomed_changeHistorical Data
2 years
| FY'24 | FY'25 | |
|---|---|---|
| Value | 14.5% | 17.1% |
| YoY Change | — | +17.9% |
Range14.5% – 17.1%
Avg YoY Growth+17.9%
Median YoY Growth+17.9%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's abiomed — % change?
- Johnson & Johnson (JNJ) reported abiomed — % change of 4.3% in Q4 2025.
- How has Johnson & Johnson's abiomed — % change changed year-over-year?
- Johnson & Johnson's abiomed — % change increased by 17.9% year-over-year, from 3.6% to 4.3%.
- What does abiomed — % change mean?
- The percentage change in revenue for the Abiomed business unit compared to a previous period.